Literature DB >> 15866316

Evidence for novel cannabinoid receptors.

Malcolm Begg1, Pál Pacher, Sándor Bátkai, Douglas Osei-Hyiaman, László Offertáler, Fong Ming Mo, Jie Liu, George Kunos.   

Abstract

Cannabinoids, including the bioactive constituents of the marijuana plant, their synthetic analogs, and endogenous lipids with cannabinoid-like activity, produce their biological effects by interacting with specific receptors. To date, two G protein-coupled cannabinoid receptors have been identified by molecular cloning, CB1 receptors mainly expressed in the brain and mediating most of the neurobehavioral effects of cannabinoids and CB2 receptors expressed by immune and hematopoietic tissues. Recent findings indicate that some cannabinoid effects are not mediated by either CB1 or CB2 receptors, and in some cases there is compelling evidence to implicate additional receptors in these actions. These include transient receptor potential vanilloid 1 (TRPV1) receptors and as-yet-unidentified receptors implicated in the endothelium-dependent vasodilator effect of certain cannabinoids and in the presynaptic inhibition of glutamatergic neurotransmission in the hippocampus. The case for these additional receptors is being reviewed here.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15866316     DOI: 10.1016/j.pharmthera.2004.11.005

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  107 in total

1.  Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator.

Authors:  X Zhang; Y Maor; J F Wang; G Kunos; J E Groopman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

Review 3.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

Review 4.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

Review 5.  Cannabinoid receptors and endocannabinoids: evidence for new players.

Authors:  Ken Mackie; Nephi Stella
Journal:  AAPS J       Date:  2006-04-28       Impact factor: 4.009

6.  Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.

Authors:  Amy K Dickason-Chesterfield; Stephanie R Kidd; Steven A Moore; John M Schaus; Bin Liu; George G Nomikos; Christian C Felder
Journal:  Cell Mol Neurobiol       Date:  2006-05-31       Impact factor: 5.046

7.  Molecular composition of the endocannabinoid system at glutamatergic synapses.

Authors:  István Katona; Gabriella M Urbán; Matthew Wallace; Catherine Ledent; Kwang-Mook Jung; Daniele Piomelli; Ken Mackie; Tamás F Freund
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

Review 8.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 9.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

10.  The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure.

Authors:  Anusha Penumarti; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2014-01-15       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.